Skip to Content

Cronos Group Inc

CRON: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$7.00GphxdPhwjhmgtx

Cronos Earnings: Decline in Gross Margin Overshadows Expense Reduction; Shares Fairly Valued

No-moat Cronos reported disappointing fourth-quarter results, with net revenue of $24 million, 4% lower sequentially. Moreover, gross margin more than halved from the third quarter to 8% due to disruptions from the Israel-Hamas war; continued oversupply in Canada pressuring prices; and unfavorable mix shift. After revisiting our assumptions, we've lowered our top-line forecast to 6% per year over the next decade, down from 8%, as we see increased competition not only in Cronos' Canadian home market but also its export markets. Additionally, we've reduced our long-term gross assumption to the high-20% range from the high-30% range. Partially offsetting these changes, Cronos has made good progress on its operating expense savings programs. We've cut our fair value estimates to $2 and CAD 2.80 per share, down from $2.50 and CAD 3.50. Shares are fairly valued, and we think US multistate operators Curaleaf and Green Thumb offer more attractive upside.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CRON so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center